Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989103 | 1.00 | P2RX7 (0.43) | P2RX7CTSSCD38AKR1B1ADH1B | |
| Acetic Acid SCHEMBL5586492 | 0.91 | CTSS (0.47) | P2RX7CTSSCD38EPHX2FFAR4 | |
| SCHEMBL3129448 | 0.84 | ADH1B (0.47) | ADH1BADH1CADH1AADH7EPHX2 | |
| SCHEMBL2575856 | 0.82 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL5536436 | 0.79 | ADH1B (0.44) | P2RX7AKR1B1ADH1BADH1CADH1A | |
| SCHEMBL8226137 | 0.78 | AKR1B1 (0.41) | P2RX7CTSSCD38AKR1B1EPHX2 | |
| SCHEMBL377351 | 0.77 | AKR1B1 (0.43) | P2RX7CTSSCD38AKR1B1EPHX2 | |
| SCHEMBL13883998 | 0.77 | P2RX7 (0.46) | P2RX7CTSSCD38AKR1B1SCN8A | |
| SCHEMBL12480863 | 0.76 | HTT (0.41) | P2RX7CD38AKR1B1ADH1BADH1C | |
| SCHEMBL3294867 | 0.75 | P2RX7 (0.57) | P2RX7CD38EPHX2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122743-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2022-11-09 | — | — | EP | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3122743-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-1434763-B1 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | AZEVAN PHARMACEUTICALS INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080090797-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | KOPPEL GARY A | 2008-02-07 | — | — | US | disclosed |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| US-20040266750-A1 | Beta-lactamyl vasopressin v1aantagonists | AZEVAN PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | P2RX7 2106/4885CTSS 150/4885CD38 1210/4885 |
| US-20080090797-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | P2RX7 1568/4885CTSS 4254/4885CD38 779/4885 |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | P2RX7 3530/4885CTSS 2905/4885CD38 472/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | P2RX7 1097/4885CTSS 505/4885CD38 319/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | P2RX7 1097/4885CTSS 505/4885CD38 319/4885 |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | P2RX7 1568/4885CTSS 4254/4885CD38 779/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | P2RX7 2106/4885CTSS 150/4885CD38 1210/4885 |
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | AVPR2, AVPR1A, AVPR1B | P2RX7 3322/4885CTSS 2338/4885CD38 450/4885 |
| US-20040266750-A1 | Beta-lactamyl vasopressin v1aantagonists | AVPR1A, AVPR2, AVPR1B | P2RX7 2608/4885CTSS 2956/4885CD38 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.